Crohn’s Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2016 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Global Crohn’s Disease Treatment Market: By Drug Class (Antibiotics, Anti-Diarrheal, Immune System Suppressants, Analgesics, Anti-Inflammatory Drugs, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Geogarphy

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

Global Crohn’s Disease Treatment Market size valued at USD 800 Mn in 2021 and expected to reach USD 1088.7 Mn by 2028, at a CAGR of 4.5% during the forecast period 2022 to 2028. Crohn’s disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohn’s disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. Crohn’s disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn’s disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat Crohn’s disease. Some of the anti-inflammatory drugs used to treat crohn’s disease include, corticosteroids and oral 5-aminosalicylates. Global Crohn’s disease treatment market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in Crohn’s disease treatment. Market players are focusing on to develop new products that can treat Crohn’s disease. For instance, mongersen, is investigational therapy for the treatment of crohn’s disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors Crohn’s disease treatment market is projected to have a lucrative opportunity for market players. Manufacturers of Crohn’s disease medications are concentrating on commercial distribution through retail pharmacies and online portals. Anti-inflammatory medications and corticosteroids are routinely distributed through these channels, both with and without a prescription. Consumers might also get savings when buying drugs in bulk through online platforms. The substantial rise of the anti-inflammatory medications segment of the global Crohn’s disease market is mostly due to easy product availability and price cuts.

Crohn's Disease Treatment Market

MARKET SUMMARY
-
4.5% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR– 4.5%
  • Largest Market– North America
  • Fastest Growing Market– Asia Pacific

Crohn’s Disease Treatment Market

  • The report on global Crohn’s Disease Treatment Market gives historical, current, and future market sizes (US$ Mn) on the basis of drug class, distribution channel and geography.
  • Crohn’s Disease Treatment Market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa
Key Players
  • Allergan, Inc. (U.S.)
  • AbbVie Inc., (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Bayer AG (Switzerland)
  • UCB S.A. (Belgium)
Dynamics

Crohn’s Disease Treatment Market

The prime driver for global Crohn’s disease treatment market is increase in number of people being infected by the disease. In addition, increase in demand for biologics and high unmet needs within the anti-TNF refractory patient group that presents untapped market opportunities. Strong pipeline and novel mechanisms to treat Crohn’s disease are fueling the growth of global Crohn’s disease treatment market . However, patent expiry of the key drugs and high cost of treatment is expected to hamper the Crohn’s disease treatment market globally. High R&D investment for development of biological drugs and unknown etiology of the Crohn’s disease further hindering the market growth.


North-America got significant share

Crohn’s Disease Treatment Market

Geographically Crohn’s drugs market is divided into five key regions, i.e. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America expected to contribute major share owing to increase in R&D activity and biologics approval to treat autoimmune disease. Furthermore, increase in prevalence and incidence of the Crohn’s disease are expected to drive the growth of the market. According to Crohn’s and Colitis Foundation of America 700,000 have crohn’s diseases in between 1992-2004, and 74% increase in doctor office visits due to crohn’s disease. Asia-Pacific region is expected to create significant growth opportunities for the market players owing to develop infrastructure, R&D activities related to biologics and increase in prevalence of Crohn’s disease in the region. Developing countries such as India and China expected to show the fastest growth owing to increase in R&D investment and healthcare expenditure in these countries

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and startup’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Crohn’s Disease Treatment Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.


Report

Table Of Content


Report

Company Profile

  • Allergan, Inc. (U.S.)
  • AbbVie Inc., (U.S.)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Bayer AG (Switzerland)
  • UCB S.A. (Belgium)
  • Perrigo Company plc (Ireland)
  • Pfizer Inc. (U.S.)
  • Johnson & Johnson Services, Inc. (U.S)
  • Ferring B.V. (Switzerland)

Description

Global Crohn’s Disease Treatment Market size valued at USD 800 Mn in 2021 and expected to reach USD 1088.7 Mn by 2028, at a CAGR of 4.5% during the forecast period 2022 to 2028. Crohn’s disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohn’s disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. Crohn’s disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn’s disease. However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat Crohn’s disease. Some of the anti-inflammatory drugs used to treat crohn’s disease include, corticosteroids and oral 5-aminosalicylates. Global Crohn’s disease treatment market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in Crohn’s disease treatment. Market players are focusing on to develop new products that can treat Crohn’s disease. For instance, mongersen, is investigational therapy for the treatment of crohn’s disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors Crohn’s disease treatment market is projected to have a lucrative opportunity for market players. Manufacturers of Crohn’s disease medications are concentrating on commercial distribution through retail pharmacies and online portals. Anti-inflammatory medications and corticosteroids are routinely distributed through these channels, both with and without a prescription. Consumers might also get savings when buying drugs in bulk through online platforms. The substantial rise of the anti-inflammatory medications segment of the global Crohn’s disease market is mostly due to easy product availability and price cuts.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX